Table 6.
Influence of conditioning regimen on engraftment
| M-200 (n = 12) | CBV (n = 13) | BEAM (n = 05) | FluCy (n = 04) | BuCy120 (n = 19) | BuCy200 (n = 03) | Cy200 (n = 05) | CyTBI (n = 04) | |
| No engraftment | 01 | 01 | 01 | |||||
| engraftment | 12 | 12 | 05 | 04 | 18 | 02 | 05 | 04 |
| Neutrophil | 11.00 | 09.00 | 19.00 | 12.50 | 19.00 | 23.50 | 19.00 | 20.00 |
| engraftment (day) | (10.00/11.50)d | (09.00/10.50)ad | (10.00/24.00)ab | (11.50/16.00)b | (18.00/23.00)cab | (22.00/25.00)cab | (18.00/29.00) | (17.50/21.00)cab |
| Platelet | 11.00 | 11.50 | 20.00 | 15.50 | 22.00 | 25.00 | 22.00 | 20.00 |
| engraftment (day) | (10.00/13.00)d | (10.00/13.00)ad | (11.00/24.00)ab | (13.50/17.50)b | (21.00/25.00)cab | (24.00/26.00)cab | (20.00/29.00) | (18.00/22.00)cab |
| OS | 12/12 (100%) | 12/13 (92.30%) | 04/05 (80.00%) | 04/04 (100%) | 18/19 (94.74%) | 02/03 (66.67%) | 04/05 | 03/04 |
| (<6 months) | (80%) | (75.00%) | ||||||
| OS | 12/12 (100%) | 10/13 (76.92%) | 04/05 (80.00%) | 04/04 (100%) | 15/19 (78.95%) | 01/03 (33.33%)* | 04/05 | 02/04 |
| (6–12 months) | (80%) | (50.00%)* |
M-200, melphalan 200 mg; CBV, cyclophosphamide + BCNU + etoposide; BEAM, BCNU + etoposide + arabynoside + melphalan; FluCy, fludarabine + cyclophosphamide; BuCy120, busulfan + cyclophosphamide 120 mg; BuCy200, busulfan + cyclophosphamide 200 mg; Cy200, cyclophosphamide 200 mg; CyTBI, cyclophosphamide + total body irradiation. Data were expressed as median (lower/upper quartile).
a
Significantly different from M-200.
b
Significantly different from CBV.
c
Significantly different from FluCy.
d
Significantly different from Cy200.
*
OS significantly different from M-200.